Neuren Pharmaceuticals Updates on Securities Buy-Back Program

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an update.

Neuren Pharmaceuticals Limited has announced an update regarding its ongoing buy-back of ordinary fully paid securities, with a total of 48,819 securities bought back on the previous day, adding to the 4,027,331 securities bought back before that. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value, reflecting a proactive approach in its financial operations.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is known for its work on treatments for conditions such as Rett syndrome and Fragile X syndrome, aiming to address unmet medical needs in these areas.

YTD Price Performance: 4.80%

Average Trading Volume: 713,249

Technical Sentiment Signal: Hold

Current Market Cap: A$1.66B

Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.